Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584)
Insulin Syringes (U-100) Use 0.3 mL / 30-unit syringes for small daily draws
Researchers investigating a collagenase-induced knee osteoarthritis model reported that AOD9604 boosted the regeneration of damaged cartilage compared to placebo (saline)
10-20 cc dose
Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance
Other research has demonstrated antioxidant effects, with DSIP activating natural protective mechanisms against oxidative stress